COSENTYX 300 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN
How to use COSENTYX 300 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet: Information for the User
Cosentyx 300 mg solution for injection in pre-filled pen
secukinumab
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor, pharmacist, or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the pack
- What is Cosentyx and what is it used for
- What you need to know before you use Cosentyx
- How to use Cosentyx
- Possible side effects
- Storage of Cosentyx
- Contents of the pack and other information
1. What is Cosentyx and what is it used for
Cosentyx contains the active substance secukinumab. Secukinumab is a monoclonal antibody that belongs to a group of medicines known as "interleukin inhibitors". It works by neutralizing the activity of a protein called IL-17A, which is present in high amounts in diseases such as psoriasis, hidradenitis suppurativa, psoriatic arthritis, and axial spondyloarthritis.
Cosentyx is used to treat the following inflammatory diseases:
- Plaque psoriasis
- Hidradenitis suppurativa
- Psoriatic arthritis
- Axial spondyloarthritis, including ankylosing spondylitis (radiographic axial spondyloarthritis) and non-radiographic axial spondyloarthritis
Plaque Psoriasis
Cosentyx is used to treat a skin condition called "plaque psoriasis" that causes inflammation of the skin. Cosentyx reduces inflammation and other symptoms of the disease. Cosentyx is used in adults, adolescents, and children (from 6 years of age) who have moderate to severe plaque psoriasis.
Using Cosentyx for plaque psoriasis will benefit you as it improves the appearance of the skin and reduces symptoms such as scaling, itching, and pain.
Hidradenitis Suppurativa
Cosentyx is used to treat a disease called hidradenitis suppurativa, also known as inverse acne or Verneuil's disease. This is a chronic and painful inflammatory skin disease. Symptoms can include painful nodules (lumps) and abscesses (boils) that can ooze pus. It commonly affects specific areas of the skin, such as under the breasts, armpits, inner thighs, groin, and buttocks. Scarring can also occur in the affected areas.
Cosentyx can reduce the number of nodules and abscesses you have and the pain that is often associated with the disease. If you have hidradenitis suppurativa, you will first be given other medicines. If you do not respond well enough to these medicines, you will be given Cosentyx.
Cosentyx is used in adults with hidradenitis suppurativa and can be used alone or with antibiotics.
Psoriatic Arthritis
Cosentyx is used to treat a condition called "psoriatic arthritis". This is an inflammatory disease of the joints, often accompanied by psoriasis. If you have active psoriatic arthritis, you will first be given other medicines. If you do not respond well enough to these medicines, you will be given Cosentyx to reduce the signs and symptoms of active psoriatic arthritis, improve physical function, and slow down damage to the cartilage and bones of the joints involved in the disease.
Cosentyx is used in adults with active psoriatic arthritis and can be used alone or with another medicine called methotrexate.
Using Cosentyx for psoriatic arthritis will benefit you as it reduces the signs and symptoms of the disease, slows down damage to the cartilage and bones of the joints, and improves your ability to perform daily activities.
Axial Spondyloarthritis, including Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) and Non-Radiographic Axial Spondyloarthritis
Cosentyx is used to treat conditions called "ankylosing spondylitis" and "non-radiographic axial spondyloarthritis". These are inflammatory diseases that mainly affect the spine, causing inflammation of the joints of the spine. If you have ankylosing spondylitis or non-radiographic axial spondyloarthritis, you will first be given other medicines. If you do not respond well enough to these medicines, you will be given Cosentyx to reduce the signs and symptoms of the disease, reduce inflammation, and improve physical function.
Cosentyx is used in adults with active ankylosing spondylitis and active non-radiographic axial spondyloarthritis.
Using Cosentyx for ankylosing spondylitis and non-radiographic axial spondyloarthritis will benefit you as it reduces the signs and symptoms of the disease and improves physical function.
2. What you need to know before you use Cosentyx
Do not use Cosentyx:
- if you are allergicto secukinumab or any of the other ingredients of this medicine (listed in section 6).
If you suspect that you are allergic, consult your doctor before using Cosentyx.
- if you have any active infectionthat your doctor considers important (e.g. active tuberculosis).
Warnings and precautions
Consult your doctor, nurse, or pharmacist before using Cosentyx:
- if you have contracted an infection.
- if you have repeated or prolonged infections.
- if you have an inflammatory disease that affects your intestine called Crohn's disease.
- if you have an inflammation of the large intestine called ulcerative colitis.
- if you have been recently vaccinated or are going to be vaccinated during treatment with Cosentyx.
- if you are undergoing any other treatment for psoriasis, such as using other immunosuppressants or phototherapy with ultraviolet (UV) light.
Tuberculosis
Tell your doctor if you have or have had tuberculosis in the past and if you have recently been in close contact with someone who has tuberculosis. Your doctor will examine you and may perform a tuberculosis test before you start using Cosentyx. If your doctor thinks you are at risk of getting tuberculosis, you may be given medicines to treat it. If you develop symptoms of tuberculosis (such as persistent cough, weight loss, lack of energy, or low-grade fever) while using Cosentyx, tell your doctor immediately.
Hepatitis B
Tell your doctor if you have or have had a hepatitis B infection in the past. This medicine may cause a reactivation of the infection. Before and during treatment with secukinumab, your doctor may examine you for signs of infection. Tell your doctor if you notice any of the following symptoms: worsening fatigue, yellowing of the skin or the white part of the eyes, dark urine, loss of appetite, nausea, and/or pain in the upper right part of the stomach.
Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis)
Stop using Cosentyx and tell your doctor or seek medical help immediately if you notice abdominal cramps and pain, diarrhea, weight loss, blood in your stool, or any other sign of intestinal problems.
Monitor for infections and allergic reactions
Cosentyx may potentially cause serious side effects, including infections and allergic reactions. You should monitor for signs of these diseases while using Cosentyx.
Stop using Cosentyx and tell your doctor or seek medical help immediately if you notice any signs that may indicate a serious infection or allergic reaction. These signs are listed in section 4 "Possible side effects".
Children and adolescents
Cosentyx is not recommended for use in children under 6 years of age with plaque psoriasis as it has not been studied in this age group.
Cosentyx is not recommended for use in children and adolescents (under 18 years of age) for other indications as it has not been studied in this age group.
Other medicines and Cosentyx
Tell your doctor or pharmacist:
- if you are taking, have taken, or might take any other medicines.
- if you have been recently vaccinated or are going to be vaccinated soon. You should not be given certain types of vaccines (live vaccines) while using Cosentyx.
Pregnancy, breastfeeding, and fertility
- It is recommended that you avoid using Cosentyx during pregnancy. The effect of this medicine on pregnant women is not known. If you are a woman of childbearing age, you are advised to avoid becoming pregnant and should use adequate contraception while using Cosentyx and for at least 20 weeks after the last dose of Cosentyx.
Consult your doctor if you are pregnant, think you may be pregnant, or plan to become pregnant.
- Consult your doctor if you are breastfeeding or plan to breastfeed. You and your doctor will decide whether you should breastfeed or use Cosentyx. You cannot do both. After using Cosentyx, you should not breastfeed for at least 20 weeks after the last dose.
Driving and using machines
Cosentyx is unlikely to affect your ability to drive or use machines.
3. How to use Cosentyx
Follow the instructions for administration of this medicine exactly as told by your doctor.
If you are unsure, consult your doctor, pharmacist, or nurse again.
Cosentyx is given by injection under the skin (i.e. subcutaneously).
You and your doctor will decide if you should inject Cosentyx yourself.
It is important that you do not try to inject the medicine until your doctor, nurse, or pharmacist has shown you how to do it. The person taking care of you can also give you the Cosentyx injection after receiving proper training.
In the section "Instructions for use of Cosentyx 300 mg in pre-filled pen UnoReady" at the end of this leaflet, you will find instructions on how to inject Cosentyx.
The instructions for use can also be found via the following QR code and website:
'QR code to be included'
www.cosentyx.eu
How much Cosentyx to use and for how long
Your doctor will decide how much Cosentyx you need and for how long.
Plaque psoriasis
Adults
- The recommended dose is 300 mg per subcutaneous injection.
- A dose of 300 mg is administered as a 300 mg injection.
After the first dose, you will receive weekly injections in weeks 1, 2, 3, and 4, followed by monthly injections. Depending on your response, your doctor may recommend additional dose adjustments. At each visit, you will receive a dose of 300 mg in a 300 mg injection.
Children from 6 years of age
- The recommended dose is based on body weight as follows:
- Weight below 25 kg: 75 mg by subcutaneous injection.
- Weight between 25 kg and below 50 kg: 75 mg by subcutaneous injection.
- Weight of 50 kg or more: 150 mg by subcutaneous injection.
Your doctor may increase the dose to 300 mg.
- Each dose of 300 mg is administered as a 300 mg injectionor as two 150 mg injections. Other formulations/concentrations may be available for the 75 mg and 150 mg doses.
After the first dose, you will receive weekly injections in weeks 1, 2, 3, and 4, followed by monthly injections.
Hidradenitis suppurativa
- The recommended dose is 300 mg per subcutaneous injection.
- Each dose of 300 mg is administered as a 300 mg injection.
After the first dose, you will receive weekly injections in weeks 1, 2, 3, and 4, followed by monthly injections. Depending on your response, your doctor may recommend additional dose adjustments.
Psoriatic arthritis
If you have psoriatic arthritis and also have moderate to severe plaque psoriasis, your doctor may adjust the recommended dose as needed.
For patients who did not respond well to medicines known as tumor necrosis factor (TNF) blockers:
- The recommended dose is 300 mg per subcutaneous injection.
- Each dose of 300 mg is administered as a 300 mg injection.
After the first dose, you will receive weekly injections in weeks 1, 2, 3, and 4, followed by monthly injections. At each visit, you will receive a dose of 300 mg in a 300 mg injection.
For other patients with psoriatic arthritis:
- The recommended dose is 150 mg per subcutaneous injection. Other formulations/concentrations are available for the 150 mg dose.
After the first dose, you will receive weekly injections in weeks 1, 2, 3, and 4, followed by monthly injections.
Depending on your response, your doctor may increase your dose to 300 mg.
Ankylosing spondylitis (Radiographic Axial Spondyloarthritis)
- The recommended dose is 150 mg per subcutaneous injection. Other formulations/concentrations are available for the 150 mg dose.
After the first dose, you will receive weekly injections in weeks 1, 2, 3, and 4, followed by monthly injections.
Depending on your response, your doctor may increase your dose to 300 mg. Each dose of 300 mg is administered as a 300 mg injection.
Non-radiographic axial spondyloarthritis
- The recommended dose is 150 mg per subcutaneous injection. Other formulations/concentrations are available for the 150 mg dose.
After the first dose, you will receive weekly injections in weeks 1, 2, 3, and 4, followed by monthly injections.
Cosentyx is a long-term treatment. Your doctor will regularly check the condition of your disease to see if the treatment is working as expected.
If you use more Cosentyx than you should
If you receive more Cosentyx than you should or the dose has been administered before the time indicated by your doctor, tell your doctor.
If you forget to use Cosentyx
If you have forgotten to inject a dose of Cosentyx, inject the next dose as soon as you remember. Then talk to your doctor to find out when you should inject the next dose.
If you stop using Cosentyx
It is not dangerous to stop using Cosentyx. However, if you do, it is possible that the symptoms of psoriasis, psoriatic arthritis, or axial spondyloarthritis may return.
If you have any other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.
4. Possible Adverse Effects
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Severe Adverse Effects
Discontinue treatment with Cosentyx and inform your doctor or seek immediate medical attention if you notice any of the following adverse effects:
Possible Severe Infection– signs may include:
- fever, flu-like symptoms, night sweats
- feeling of fatigue or difficulty breathing, persistent cough
- hot, red, and painful skin to the touch, or painful rash with blisters
- burning when urinating.
Severe Allergic Reaction– signs may include:
- difficulty breathing or swallowing
- low blood pressure, which can cause dizziness or slight dizziness
- swelling of the face, lips, tongue, or throat
- intense itching of the skin accompanied by rash or blisters.
Your doctor will decide whether you should and when to restart treatment.
Other Adverse Effects
Most of the following adverse effects are mild or moderate. If they become severe, inform your doctor, pharmacist, or nurse.
Very Common(may affect more than 1 in 10 people):
- upper respiratory tract infections with symptoms such as sore throat and nasal congestion (rhinopharyngitis, rhinitis).
Common(may affect up to 1 in 10 people):
- mouth ulcers (oral herpes)
- diarrhea
- nasal discharge (rhinorrhea)
- headache
- nausea
- fatigue
- itching, redness, and dryness of the skin (eczema)
Uncommon(may affect up to 1 in 100 people):
- oral thrush (oral candidiasis)
- signs of white blood cell deficiency, such as fever, sore throat, or mouth ulcers due to infections (neutropenia)
- infection of the outer ear (otitis externa)
- eye discharge with itching, redness, and swelling (conjunctivitis)
- itchy rash (urticaria)
- lower respiratory tract infections
- abdominal cramps, abdominal pain, diarrhea, weight loss, or blood in the stool (signs of intestinal problems)
- small blisters with itching on the palms of the hands, soles of the feet, and edges of the fingers and toes (dyshidrotic eczema)
- athlete's foot (tinea pedis)
Rare(may affect up to 1 in 1,000 people):
- severe allergic reaction with shock (anaphylactic reaction)
- redness and peeling of the skin over a large area of the body, which may be itchy or painful (exfoliative dermatitis)
- inflammation of small blood vessels, which can lead to a skin rash with small red or purple bumps (vasculitis)
- swelling of the neck, face, mouth, or throat that can lead to difficulty swallowing or breathing (angioedema)
Frequency Not Known(cannot be estimated from available data):
- fungal infections of the skin and mucous membranes (including esophageal candidiasis)
- painful swelling and ulceration of the skin (pyoderma gangrenosum)
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.
5. Storage of Cosentyx
Keep this medicine out of sight and reach of children.
Do not use this medicine:
- after the expiration date that appears on the box or on the label of the pen after "CAD"/"EXP".
Store the sealed pen in its box to protect it from light. Store in the refrigerator between 2°C and 8°C. Do not freeze. Do not shake.
If necessary, Cosentyx can be left out of the refrigerator for a single period of up to 4 days at room temperature, not exceeding 30°C.
This medicine is for single use.
Medicines should not be disposed of through wastewater. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
6. Package Contents and Additional Information
Cosentyx Composition
- The active ingredient is secukinumab. Each preloaded pen contains 300 mg of secukinumab.
- The other components are trehalose dihydrate, histidine, histidine hydrochloride monohydrate, methionine, polysorbate 80, and water for injectable preparations.
Appearance of Cosentyx and Package Contents
Cosentyx injectable solution is a clear liquid. Its color varies from colorless to slightly yellow.
Cosentyx 300 mg injectable solution in a preloaded pen is presented in a package that contains 1 preloaded pen and in multiple packages that contain 3 (3 packages of 1) preloaded pens. Not all package sizes may be marketed.
Marketing Authorization Holder
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland
Manufacturer
Novartis Pharma GmbH
Roonstraße 25
90429 Nuremberg
Germany
Sandoz GmbH
Biochemiestrasse 10
6336 Langkampfen
Austria
Novartis Pharmaceutical Manufacturing GmbH
Biochemiestrasse 10
6336 Langkampfen
Austria
Novartis Pharma GmbH
Sophie-Germain-Strasse 10
90443 Nürnberg
Germany
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien Novartis Pharma N.V. Tel: +32 2 246 16 11 | Lietuva SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16 50 |
| Luxembourg/Luxemburg Novartis Pharma N.V. Tel: +32 2 246 16 11 |
Ceská republika Novartis s.r.o. Tel: +420 225 775 111 | Magyarország Novartis Hungária Kft. Tel: +36 1 457 65 00 |
Danmark Novartis Healthcare A/S Tel: +45 39 16 84 00 | Malta Novartis Pharma Services Inc. Tel: +356 2122 2872 |
Deutschland Novartis Pharma GmbH Tel: +49 911 273 0 | Nederland Novartis Pharma B.V. Tel: +31 88 04 52 111 |
Eesti SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 810 | Norge Novartis Norge AS Tel: +47 23 05 20 00 |
Ελλáδα Novartis (Hellas) A.E.B.E. Tel: +30 210 281 17 12 | Österreich Novartis Pharma GmbH Tel: +43 1 86 6570 |
España Novartis Farmacéutica, S.A. Tel: +34 93 306 42 00 | Polska Novartis Poland Sp. z o.o. Tel: +48 22 375 4888 |
France Novartis Pharma S.A.S. Tel: +33 1 55 47 66 00 | Portugal Novartis Farma - Produtos Farmacêuticos, S.A. Tel: +351 21 000 8600 |
Hrvatska Novartis Hrvatska d.o.o. Tel: +385 1 6274 220 | România Novartis Pharma Services Romania SRL Tel: +40 21 31299 01 |
Ireland Novartis Ireland Limited Tel: +353 1 260 12 55 | Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 50 |
Ísland Vistor hf. Tel: +354 535 7000 | Slovenská republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5439 |
Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 | Suomi/Finland Novartis Finland Oy Tel: +358 (0)10 6133 200 |
Κúπρος Novartis Pharma Services Inc. Tel: +357 22 690 690 | Sverige Novartis Sverige AB Tel: +46 8 732 32 00 |
Latvija SIA Novartis Baltics Tel: +371 67 887 070 |
Date of Last Revision of this Leaflet:11/2024
Other Sources of Information
Detailed information about this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu
Instructions for Use of Cosentyx 300 mg in UnoReady Pen
secukinumab

Your Cosentyx 300 mg in UnoReady Pen:
| Do not usethe UnoReady Pen of Cosentyx if the seal of the outer box is broken. Keep the UnoReady Pen of Cosentyx in the sealed outer box until you are ready to use it to protect it from light. Keep Cosentyx in UnoReady Pen in the refrigeratorbetween 2°C and 8°C and out of the reach of children.
The needle is covered by the needle protector and is not visible. Do not touch or push the needle protector because you could suffer a needlestick injury. |
Shown above is Cosentyx 300 mg in UnoReady Pen without cap. Do notremove the cap until you are ready to administer the injection. |
What you need for the injection:
Included in the box: A new and unused Cosentyx 300 mg UnoReady Pen.
| Not included in the box:
|
|
Before the injection:
Remove Cosentyx 300 mg in UnoReady Pen from the refrigerator 30 to 45 minutesbefore the injection to allow it to reach room temperature.
|
Through the "Window": The liquid should be clear. Its color may vary from colorless to slightly yellowish. Do not useif the liquid contains particles, is cloudy, or has a clearly brown color. You may see small air bubbles, which is normal. Through the "Expiration Date": Check the expiration date (EXP) on your Cosentyx in UnoReady Pen. Do not usethe pen if it has passed the expiration date. Check that your pen contains the correct medicine and dose. Contact your pharmacist if the pen does not meet any of these requirements. |
| 2a. Choose an injection site:
2b. Only caregivers or healthcare professionals:
|
|
|
The Injection:
|
|
|
|
|
|
The green indicator with the gray tipwill indicate the progress of the injection. |
|
|
After the injection:
|
|
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to COSENTYX 300 mg SOLUTION FOR INJECTION IN A PRE-FILLED PENDosage form: INJECTABLE, 150mg/1mlActive substance: secukinumabManufacturer: Novartis Europharm LimitedPrescription requiredDosage form: INJECTABLE, 150 mg secukinumab / mlActive substance: secukinumabManufacturer: Novartis Europharm LimitedPrescription requiredDosage form: INJECTABLE, 150 mg secukinumab / mlActive substance: secukinumabManufacturer: Novartis Europharm LimitedPrescription required
Online doctors for COSENTYX 300 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN
Discuss questions about COSENTYX 300 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions














